glp-1 and anesthesia Anesthetic Considerations for Patients Taking Glucagon-Like Peptide-1 Agonists Perioperative management of patients taking

In this trial, 69 to 79% of the participants lost weight with an average weight reduction of 10% after 68 weeks of treatment compared with placebo group (1217%) ( Similarly, in the Peptide Innovation for Early Diabetes Treatment (PIONEER) clinical trial, oral semaglutide was tested in patients with DM2

Actual results may differ significantly

US Department of Health and Human Services

Research shows: Slowed progression of chronic kidney disease (CKD) Reduced proteinuria (albumin in urine) , an early marker of kidney damage Improved kidney filtration rates over time The FLOW trial with semaglutide demonstrated that GLP-1 therapy could significantly reduce the risk of kidney failure in patients with type 2 diabetes and CKD

GLP-1 medications can help you recognize these signals better

A lawyer specializing in pharmaceutical litigation, particularly GLP-1 drugs personal injury cases, can evaluate your situation, explain your rights, and determine the best course of action